Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
63.11
-1.07 (-1.67%)
At close: Dec 26, 2025, 4:00 PM EST
62.66
-0.45 (-0.71%)
After-hours: Dec 26, 2025, 7:51 PM EST
Cytokinetics Stock Forecast
Stock Price Forecast
The 16 analysts that cover Cytokinetics stock have a consensus rating of "Strong Buy" and an average price target of $82.38, which forecasts a 30.53% increase in the stock price over the next year. The lowest target is $41 and the highest is $136.
Price Target: $82.38 (+30.53%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 6 |
| Buy | 7 | 7 | 9 | 9 | 8 | 8 |
| Hold | 3 | 3 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 16 | 16 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $65 → $71 | Buy | Maintains | $65 → $71 | +12.50% | Dec 23, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $87 → $95 | Buy | Maintains | $87 → $95 | +50.53% | Dec 22, 2025 |
| Barclays | Barclays | Buy Maintains $82 → $87 | Buy | Maintains | $82 → $87 | +37.85% | Dec 22, 2025 |
| Citizens | Citizens | Buy Maintains $78 → $88 | Buy | Maintains | $78 → $88 | +39.44% | Dec 22, 2025 |
| Needham | Needham | Strong Buy Maintains $72 → $84 | Strong Buy | Maintains | $72 → $84 | +33.10% | Dec 22, 2025 |
Financial Forecast
Revenue This Year
82.47M
from 18.47M
Increased by 346.43%
Revenue Next Year
130.05M
from 82.47M
Increased by 57.69%
EPS This Year
-6.51
from -5.26
EPS Next Year
-5.94
from -6.51
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 161.5M | 214.2M | ||||
| Avg | 82.5M | 130.1M | ||||
| Low | 68.6M | 53.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 774.3% | 159.7% | ||||
| Avg | 346.4% | 57.7% | ||||
| Low | 271.3% | -35.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.20 | -4.70 | ||||
| Avg | -6.51 | -5.94 | ||||
| Low | -7.05 | -7.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.